Tamoxifen and Ovarian Cancer: When a Breast Cancer Drug Becomes Part of Your Story

Tamoxifen and ovarian cancer have a relationship that’s worth understanding clearly, especially if you’re navigating treatment options or trying to make sense of what your doctor is recommending.

Most people know tamoxifen as a breast cancer drug. But tamoxifen also has a role in certain types of ovarian cancer, particularly in cases that have come back after chemotherapy, and in specific subtypes like ovarian stromal tumors and, increasingly, low-grade serous ovarian cancer (LGSOC).

What Is Tamoxifen?

Tamoxifen is a drug called a selective estrogen receptor modulator, or SERM. SERMs work by blocking estrogen from attaching to cancer cells, occupying the receptor so estrogen can’t latch on and trigger growth signals.

That’s different from how aromatase inhibitors like letrozole and anastrozole work. Those drugs reduce the amount of estrogen your body produces in the first place. Tamoxifen doesn’t lower estrogen levels; it just gets in the way of estrogen doing its job at the cellular level.

Estrogen can fuel the growth of certain cancers. Tamoxifen gets in the way of that process: it occupies the receptor on a cancer cell so estrogen can’t latch on and send signals that encourage growth.

Read more: “Hormone Therapy for Ovarian Cancer: Unlocking New Possibilities in Treatment”

It comes in pill form, typically 20 mg per day, which makes it easy to take at home. That convenience, combined with its relatively mild side effect profile, is part of why doctors consider it in situations where stronger chemotherapy for ovarian cancer may not be the right fit.

How Is Tamoxifen Used in Ovarian Cancer?

This is where it gets nuanced. Tamoxifen for ovarian cancer is not a one-size-fits-all treatment. Its role depends heavily on the type of ovarian cancer involved.

Ovarian Stromal Tumors

The American Cancer Society recognizes tamoxifen as a treatment option for ovarian stromal tumors, a type of tumor that originates in the structural tissue of the ovaries and often produces estrogen itself. Because these tumors are hormone-driven, blocking estrogen makes sense as part of the treatment strategy.

Recurrent or Advanced Epithelial Ovarian Cancer

For the more common epithelial ovarian cancers — especially when the cancer has returned after chemotherapy — tamoxifen is sometimes used as a later-line option when other treatments have been exhausted or when a patient’s quality of life is a priority.

One research study found that among 30 patients with persistent or recurrent epithelial ovarian cancer, 2 had complete remissions and 10 had disease stabilization lasting an average of 11.5 months, with no significant toxicity. One complete remission lasted 41 months. Those aren’t dramatic numbers, but for patients who’ve run out of other options, stable disease can mean real time and real quality of life.

A larger review found an overall objective response rate of about 11%, with wide variation between studies (ranging from 0% to 56%). Another study showed a clinical benefit rate of 56%: meaning, more than half of patients who took tamoxifen for at least two months saw their disease either shrink, partially respond, or hold steady. The majority of those fell into the “stable disease” category.

That’s not a cure, but it can matter enormously to someone managing ovarian cancer as a long-term condition.

Low-Grade Serous Ovarian Cancer (LGSOC)

This is where tamoxifen in ovarian cancer is becoming an increasingly important conversation. LGSOC is a subtype that tends to affect younger women — often in their 40s — and to which standard chemotherapy is often less effective. Because LGSOC is considered a hormone-sensitive cancer, hormone therapy plays a more central role in its management than in other ovarian cancer types.

Tamoxifen is one of the hormone-based options used for LGSOC, alongside aromatase inhibitors like letrozole and anastrozole.

What Does “Clinical Benefit” Actually Mean?

When researchers talk about tamoxifen producing a “clinical benefit,” they generally mean one of three things:

• Complete response: All detectable signs of cancer disappear
• Partial response: The cancer shrinks significantly (usually defined as at least a 50% reduction)
• Stable disease: The cancer stops growing or progressing

In one study, most patients who benefited fell into the stable disease category. And while that might not sound exciting, this can be meaningful for someone managing ovarian cancer recurrence, halting progression — sometimes for months or even years.

How Does Tamoxifen Compare to Chemotherapy?

For patients with platinum-resistant ovarian cancer (meaning the cancer returned within six months of platinum-based chemotherapy), the Ovaresist trial compared tamoxifen directly to single-agent chemotherapy across 238 patients. 

The chemotherapy group had longer progression-free survival: 12.7 weeks versus 8.3 weeks for tamoxifen. But patients on chemotherapy experienced significantly more toxicity and a worse quality of life, including a greater worsening of social functioning. Overall survival was the same in both groups.

That trade-off is real, and it matters. For patients who have already been through multiple rounds of chemotherapy, tamoxifen offers a gentler path: oral, at home, with manageable side effects.

What Are the Side Effects of Tamoxifen?

Tamoxifen’s side effects are generally milder than chemotherapy, which is one of the reasons it’s appealing in later-stage treatment. That said, they’re worth knowing about.

Common side effects include:

• Hot flashes
• Vaginal dryness or discharge
• Nausea
• Mood changes
• Hair thinning
• Changes in the menstrual cycle

More serious side effects to watch for:

• Blood clots (deep vein thrombosis) — tamoxifen increases clotting risk
• Cataracts
• Changes in bone density
• Increased risk of endometrial (uterine) cancer in postmenopausal women, though this is less relevant for many ovarian cancer patients who’ve had a hysterectomy as part of their treatment

Tamoxifen can interact with certain other medications, including some antidepressants (like fluoxetine and paroxetine), some heart medications, and certain antifungals. Always tell your doctor about every medication you’re taking before starting tamoxifen.

Does Estrogen Receptor Status Predict Response?

Ovarian cancers frequently carry estrogen receptors, which is the biological reason tamoxifen was proposed for them in the first place. But testing positive for estrogen receptors doesn’t reliably predict whether tamoxifen will actually work. Multiple studies found no statistically significant correlation between receptor status and response.

What this means practically: your doctor may not rely on receptor testing alone when deciding whether tamoxifen is worth trying.

Is Tamoxifen Relevant in an Era of Targeted Therapy?

It’s a fair question. Newer treatments — including PARP inhibitors, MEK inhibitors like trametinib, and combination therapies like avutometinib plus defactinib — have transformed the landscape for certain ovarian cancer subtypes, especially LGSOC.

But tamoxifen hasn’t been replaced. Here’s why:

• It’s oral and doesn’t require IV infusions
• Its side effect profile is far more tolerable than most alternatives
• It’s significantly less expensive than newer targeted therapies
• It remains accessible in countries and health systems where newer drugs are unaffordable or unavailable

Tamoxifen may still have a role even in the era of molecular targeted therapy, particularly for patients who have progressed through multiple lines of chemotherapy, prefer quality of life over aggressive treatment, or for whom newer drugs are not an option.

Questions to Ask Your Doctor

If tamoxifen has come up in your treatment discussions, here are some questions worth bringing to your next appointment:

• Does my cancer type or subtype respond to hormone-blocking therapy?
• Have my tumor’s estrogen receptor levels been tested?
• How does tamoxifen compare to other hormone therapies like letrozole or anastrozole for my situation?
• What would stable disease look like for me, and how would we measure it?
• What are the most likely side effects given my specific health history?
• Are there any medications I’m currently taking that could interact with tamoxifen?

For a broader list of questions to bring to your oncologist, see our guide to essential ovarian cancer questions.

Where Does Tamoxifen Fit in Your Treatment Picture?

Tamoxifen and ovarian cancer is not a simple story. This drug isn’t a frontline treatment for most patients, and it’s not a cure. But it has a real (if modest) role in specific situations: ovarian stromal tumors, recurrent disease where chemotherapy options are limited, and hormone-sensitive subtypes like LGSOC.

Its convenience, relatively more manageable side effects, and low cost make it a practical option when other doors have closed. And for some patients, it buys meaningful time.

Understanding ovarian cancer treatment options in full, including the less-discussed ones like tamoxifen, is part of how patients advocate for themselves and ask better questions. That matters. It can change outcomes.